– USA, FL – Apotheca Biosciences (OTC:PCFP), a biopharmaceutical company, which engages in discovering, developing, and commercializing cannabinoid-based medicines for Opioid crisis, Neuropathic pain, Cancer, Alzheimer’s, Parkinson, Sleep disorder and Immune Enhancement, announces today that it has elected Dr. P.C. Sundar as its Chairman & CEO effective February 1, 2019.
Dr. Sundar, through his years of experience working for Fortune 100 pharmaceutical companies, will lead the Company in discovering, developing, and commercializing cannabinoid-based medicines for Opioid crisis, Neuropathic pain, Cancer, Alzheimer’s and Parkinson.
Dr. Sundar has over 30 years’ executive leadership experience in the pharmaceutical industries. As the CEO of Apotheca, he brings expertise in growing and scaling businesses, developing winning strategies, operations, marketing, sales and innovation for global businesses and broad brand portfolios. During his 30-year career at Abbott Labs, and Bayer, Sundar held positions of increasing responsibility with strong proven results. Before joining the Apotheca team, Sundar most recently served as a Senior Vice President of a Fortune 50 pharmaceutical company. He has brought several FDA-approved drugs to market. He also built several collaborative ventures for these companies. Sundar’s experience in the pharma sector is helping Apotheca to be a lead player in endocannabinoid drug discovery. Sundar earned his PhD degree from Vanderbilt University.
Apotheca is positioning to be a world-class research and development facility in endocannabinoid drug development. Apotheca plans to set-up a state-of-the-art research and development lab to enhance the BPRx platform and rapidly expand its research capabilities. Apotheca’s research includes specific programs for Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease and severe, chronic pain. For each of these diseases, there is a dire need for new therapies. Depending on the disease, our therapies will use a BPRx platform to optimize the synergistic combination of photo and endocannabinoids to modulate disease pathology and progression. By significantly decreasing the production of relevant signaling and causative molecules at targeted sites within various tissue systems, the goal is to address the underlying biology of the disease and make a meaningful difference for patients. Our talented team of scientists, scientific advisers, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Apotheca Biosciences is at the forefront of medical technologies with the development of a CBD pain patch for the healthcare and consumer care industry. This acquisition will provide knowledge and expertise to the development of this CBD product, along with our other products. Our pipeline of products includes transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids.
Apotheca Biosciences is a pioneering biotech company with an emphasis in research and development in addition to the creation of high-grade nutraceuticals and cosmetics. The health of our customers takes precedence and our solid business strategy ensures focus on customer well-being. Our goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects our strategy and research.
About Apotheca Biosciences Inc.
Apotheca Biosciences, a biopharmaceutical company, through its divisions, engages in 1) the discovery, development, and commercialization of therapies for the treatment of opioid addiction, sleep disorder, PTSD. Alzheimer’s and inflammatory diseases worldwide, 2) develops and manufactures medical devices for precise dosing, and 3) direct to business and consumer CBD enhanced supplements, formulations and cosmetics. The pipeline of products includes, transdermal, sublingual, digestive technologies and medical devices for precise and controlled dosing of cannabinoids. Products such as CannaDERME, a transdermal technology using nano-emulsion for fast absorption of cannabinoid compounds for the general pain market.
For more information : http://www.apothecabiosciences.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
